The functional effects of the BET bromodomain inhibition observed in our Ewing Sarcoma models are indeed attributable to the strong reduction in the oncogenic-driver EWS-Fli1 expression, which are both dose- and time-dependent. This evidence concerns the gene FLI1 and Ewing sarcoma.